Institutional shares held 1.24 Billion
23.4M calls
13M puts
Total value of holdings $206B
$3.9B calls
$2.16B puts
Market Cap $294B
1,768,099,968 Shares Out.
Institutional ownership 70.17%
# of Institutions 3,563


Latest Institutional Activity in ABBV

Top Purchases

Q1 2024
Global Assets Advisory, LLC Shares Held: 873K ($145M)
Q1 2024
Aegon Asset Management Uk PLC Shares Held: 430K ($71.5M)
Q1 2024
Svenska Handelsbanken Ab (Publ) Shares Held: 183K ($30.4M)
Q1 2024
Norden Group LLC Shares Held: 140K ($23.2M)
Q1 2024
Campbell Newman Asset Management Inc Shares Held: 115K ($19.2M)

Top Sells

Q1 2024
Los Angeles Capital Management LLC Shares Held: 168K ($28M)
Q1 2024
Exchange Traded Concepts, LLC Shares Held: 96.2K ($16M)
Q1 2024
Sumitomo Mitsui Trust Holdings, Inc. Shares Held: 4.37M ($727M)
Q1 2024
Stratos Wealth Advisors, LLC Shares Held: 24.6K ($4.09M)
Q1 2024
Gateway Investment Advisers LLC Shares Held: 441K ($73.5M)

About ABBV

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.


Insider Transactions at ABBV

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
857K Shares
From 29 Insiders
Grant, award, or other acquisition 676K shares
Acquisition or disposition by will or laws 129 shares
Exercise of conversion of derivative security 180K shares
Sell / Disposition
895K Shares
From 24 Insiders
Payment of exercise price or tax liability 292K shares
Open market or private sale 554K shares
Bona fide gift 46.2K shares
Sale (or disposition) back to the issuer 2.92K shares

Track Institutional and Insider Activities on ABBV

Follow AbbVie Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ABBV shares.

Notify only if

Insider Trading

Get notified when an Abb Vie Inc. insider buys or sells ABBV shares.

Notify only if

News

Receive news related to AbbVie Inc.

Track Activities on ABBV